Limits...
Acupoint injection of onabotulinumtoxin A for migraines.

Hou M, Xie JF, Kong XP, Zhang Y, Shao YF, Wang C, Ren WT, Cui GF, Xin L, Hou YP - Toxins (Basel) (2015)

Bottom Line: Injection of a small amount of drug at acupuncture points is an innovation as compared to traditional acupuncture.The variations between baseline and BoNTA post-injection for four months were calculated monthly as outcome measures.BoNTA injections at fixed-sites and acupoint-sites significantly reduced the migraine attack frequency, intensity, duration and associated symptoms for four months compared with placebo (p < 0.01).

View Article: PubMed Central - PubMed

Affiliation: Department of Neuroscience, Anatomy, Histology and Embryology, Key Laboratory of Preclinical Study for New Drugs of Gansu Province, School of Basic Medical Sciences, Lanzhou University, 199 Donggang Xi Road, Lanzhou 730000, China. sunny_smile_824@163.com.

ABSTRACT
Onabotulinumtoxin A (BoNTA) has been reported to be effective in the therapy for migraines. Acupuncture has been used worldwide for the treatment of migraine attacks. Injection of a small amount of drug at acupuncture points is an innovation as compared to traditional acupuncture. The purpose of this study was to evaluate and compare the effectiveness of fixed (muscle)-site and acupoint-site injections of BoNTA for migraine therapy in a randomized, double-blinded, placebo-controlled clinical trial extending over four months. Subjects with both episodic and chronic migraines respectively received a placebo (n = 19) or BoNTA (2.5 U each site, 25 U per subject) injection at fixed-sites (n = 41) including occipitofrontalis, corrugator supercilii, temporalis and trapeziue, or at acupoint-sites (n = 42) including Yintang (EX-HN3), Taiyang (EX-HN5), Baihui (GV20), Shuaigu (GB8), Fengchi (GB20) and Tianzhu (BL10). The variations between baseline and BoNTA post-injection for four months were calculated monthly as outcome measures. BoNTA injections at fixed-sites and acupoint-sites significantly reduced the migraine attack frequency, intensity, duration and associated symptoms for four months compared with placebo (p < 0.01). The efficacy of BoNTA for migraines in the acupoint-site group (93% improvement) was more significant than that in the fixed-site group (85% improvement) (p < 0.01). BoNTA administration for migraines is effective, and at acupoint-sites shows more efficacy than at fixed-sites. Further blinded studies are necessary to establish the efficacy of a low dose toxin (25 U) introduced with this methodology in chronic and episodic migraines.

Show MeSH

Related in: MedlinePlus

Schematic sites of fixed-sites injection. These sites (●) are respectively located at frontal and occipital belly of occipitofrontalis, corrugator supercilii, temporalis and superior part of trapeziue muscle.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4663513&req=5

toxins-07-04442-f001: Schematic sites of fixed-sites injection. These sites (●) are respectively located at frontal and occipital belly of occipitofrontalis, corrugator supercilii, temporalis and superior part of trapeziue muscle.

Mentions: Subjects were randomized 2:2:1 to receive fixed-sites, or acupoint-sites of BoNTA or placebo injections. In order to maintain the double-blind protocol, a research coordinator who was not directly involved with the subjects managed the randomization and preparation of injections. The application sites of placebo and fixed-sites groups were respectively at frontal and occipital belly of occipitofrontalis, corrugator supercilii, temporalis and superior part of trapeziue (Figure 1), which have been mostly selected to treat migraine with BoNTA in previous studies [12,14,19,45,50].


Acupoint injection of onabotulinumtoxin A for migraines.

Hou M, Xie JF, Kong XP, Zhang Y, Shao YF, Wang C, Ren WT, Cui GF, Xin L, Hou YP - Toxins (Basel) (2015)

Schematic sites of fixed-sites injection. These sites (●) are respectively located at frontal and occipital belly of occipitofrontalis, corrugator supercilii, temporalis and superior part of trapeziue muscle.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4663513&req=5

toxins-07-04442-f001: Schematic sites of fixed-sites injection. These sites (●) are respectively located at frontal and occipital belly of occipitofrontalis, corrugator supercilii, temporalis and superior part of trapeziue muscle.
Mentions: Subjects were randomized 2:2:1 to receive fixed-sites, or acupoint-sites of BoNTA or placebo injections. In order to maintain the double-blind protocol, a research coordinator who was not directly involved with the subjects managed the randomization and preparation of injections. The application sites of placebo and fixed-sites groups were respectively at frontal and occipital belly of occipitofrontalis, corrugator supercilii, temporalis and superior part of trapeziue (Figure 1), which have been mostly selected to treat migraine with BoNTA in previous studies [12,14,19,45,50].

Bottom Line: Injection of a small amount of drug at acupuncture points is an innovation as compared to traditional acupuncture.The variations between baseline and BoNTA post-injection for four months were calculated monthly as outcome measures.BoNTA injections at fixed-sites and acupoint-sites significantly reduced the migraine attack frequency, intensity, duration and associated symptoms for four months compared with placebo (p < 0.01).

View Article: PubMed Central - PubMed

Affiliation: Department of Neuroscience, Anatomy, Histology and Embryology, Key Laboratory of Preclinical Study for New Drugs of Gansu Province, School of Basic Medical Sciences, Lanzhou University, 199 Donggang Xi Road, Lanzhou 730000, China. sunny_smile_824@163.com.

ABSTRACT
Onabotulinumtoxin A (BoNTA) has been reported to be effective in the therapy for migraines. Acupuncture has been used worldwide for the treatment of migraine attacks. Injection of a small amount of drug at acupuncture points is an innovation as compared to traditional acupuncture. The purpose of this study was to evaluate and compare the effectiveness of fixed (muscle)-site and acupoint-site injections of BoNTA for migraine therapy in a randomized, double-blinded, placebo-controlled clinical trial extending over four months. Subjects with both episodic and chronic migraines respectively received a placebo (n = 19) or BoNTA (2.5 U each site, 25 U per subject) injection at fixed-sites (n = 41) including occipitofrontalis, corrugator supercilii, temporalis and trapeziue, or at acupoint-sites (n = 42) including Yintang (EX-HN3), Taiyang (EX-HN5), Baihui (GV20), Shuaigu (GB8), Fengchi (GB20) and Tianzhu (BL10). The variations between baseline and BoNTA post-injection for four months were calculated monthly as outcome measures. BoNTA injections at fixed-sites and acupoint-sites significantly reduced the migraine attack frequency, intensity, duration and associated symptoms for four months compared with placebo (p < 0.01). The efficacy of BoNTA for migraines in the acupoint-site group (93% improvement) was more significant than that in the fixed-site group (85% improvement) (p < 0.01). BoNTA administration for migraines is effective, and at acupoint-sites shows more efficacy than at fixed-sites. Further blinded studies are necessary to establish the efficacy of a low dose toxin (25 U) introduced with this methodology in chronic and episodic migraines.

Show MeSH
Related in: MedlinePlus